BACKGROUND: Sub-Saharan Africa experiences an epidemic surge in hypertension. Studies in African Americans led to the recommendation to initiate antihypertensive treatment in Blacks with a diuretic or a low-dose fixed combination including a diuretic. We mounted the Newer versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial to compare in native African patients a fixed combination of newer drugs, not involving a diuretic, with a combination of older drugs including a diuretic. METHODS:Patients aged 30-69 years with uncomplicated hypertension (140-179/90-109 mmHg) and two or fewer associated risk factors are eligible. After a 4-week run-in period off treatment, 180 patients will be randomized to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg or amlodipine/valsartan 5/160 mg. To attain and maintain blood pressure below 140/90 mmHg during 6 months of follow-up, the doses of bisoprolol and amlodipine in the combination tablets will be increased to 10 mg/day with the possible addition of α-methyldopa or hydralazine. NOAAH is powered to demonstrate a 5-mmHg between-group difference in sitting systolic pressure with a two-sided p-value of 0.01 and 90% power. NOAAH is investigator-led and complies with the Helsinki declaration. RESULTS: Six centers in four sub-Saharan countries started patient recruitment on September 1, 2010. On December 1, 195 patients were screened, 171 were enrolled, and 51 were randomized and followed up. The trial will be completed in the third quarter of 2011. CONCLUSIONS:NOAAH (NCT01030458) is the first randomized multicenter trial of antihypertensive medications in hypertensive patients born and living in sub-Saharan Africa.
RCT Entities:
BACKGROUND: Sub-Saharan Africa experiences an epidemic surge in hypertension. Studies in African Americans led to the recommendation to initiate antihypertensive treatment in Blacks with a diuretic or a low-dose fixed combination including a diuretic. We mounted the Newer versus Older Antihypertensive Agents in African HypertensivePatients (NOAAH) trial to compare in native African patients a fixed combination of newer drugs, not involving a diuretic, with a combination of older drugs including a diuretic. METHODS:Patients aged 30-69 years with uncomplicated hypertension (140-179/90-109 mmHg) and two or fewer associated risk factors are eligible. After a 4-week run-in period off treatment, 180 patients will be randomized to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg or amlodipine/valsartan 5/160 mg. To attain and maintain blood pressure below 140/90 mmHg during 6 months of follow-up, the doses of bisoprolol and amlodipine in the combination tablets will be increased to 10 mg/day with the possible addition of α-methyldopa or hydralazine. NOAAH is powered to demonstrate a 5-mmHg between-group difference in sitting systolic pressure with a two-sided p-value of 0.01 and 90% power. NOAAH is investigator-led and complies with the Helsinki declaration. RESULTS: Six centers in four sub-Saharan countries started patient recruitment on September 1, 2010. On December 1, 195 patients were screened, 171 were enrolled, and 51 were randomized and followed up. The trial will be completed in the third quarter of 2011. CONCLUSIONS: NOAAH (NCT01030458) is the first randomized multicenter trial of antihypertensive medications in hypertensivepatients born and living in sub-Saharan Africa.
Authors: Augustine N Odili; Birinus Ezeala-Adikaibe; Mouhamadou B Ndiaye; Benedict C Anisiuba; Marius M Kamdem; Chinwuba K Ijoma; Joseph Kaptue; Hilaire J Boombhi; Philip M Kolo; Elvis N Shu; Lutgarde Thijs; Jan A Staessen; Babatunde A Omotoso; Samuel Kingue; Serigne A Ba; Daniel Lemogoum; Jean-René M'Buyamba-Kabangu; Ifeoma I Ulasi Journal: Trials Date: 2012-05-17 Impact factor: 2.279
Authors: J R M'Buyamba-Kabangu; B C Anisiuba; M B Ndiaye; D Lemogoum; L Jacobs; C K Ijoma; L Thijs; H J Boombhi; J Kaptue; P M Kolo; J B Mipinda; C E Osakwe; A Odili; B Ezeala-Adikaibe; S Kingue; B A Omotoso; S A Ba; I I Ulasi; J A Staessen Journal: J Hum Hypertens Date: 2013-06-27 Impact factor: 3.012
Authors: Chukwunomso E Osakwe; Lotte Jacobs; Benedict C Anisiuba; Mouhamado B Ndiaye; Daniel Lemogoum; Chinwuba K Ijoma; Marius M Kamdem; Lutgarde Thijs; Hilaire J Boombhi; Joseph Kaptue; Philip M Kolo; Jean B Mipinda; Augustine N Odili; Birinus Ezeala-Adikaibe; Samuel Kingue; Babatunde A Omotoso; Serigne A Ba; Ifeoma I Ulasi; Jean-Rene M'buyamba-Kabangu; Jan A Staessen Journal: Blood Press Date: 2013-09-25 Impact factor: 2.835